Development and comparative evaluation of three new generation BRSV DIVA vaccines and a corresponding DIVA test

三种新一代 BRSV DIVA 疫苗的开发和比较评价以及相应的 DIVA 试验

• 批准号: BB/I017216/1
• 负责人: Geraldine Taylor
• 金额: $ 50.83万
• 依托单位: The Pirbright Institute
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FI017216%2F1
• 关键词: Development; comparative; evaluation; three; new

Bovine Respiratory Syncytial Virus (BRSV) is the single most important viral respiratory pathogen of calves causing high morbidity and mortality in the European cattle industry. The extensive use of antibiotics to control secondary infections following BRSV increases the likelihood of the emergence of antibiotic-resistant bacteria. Consequently, the impact of BRSV on economics, animal welfare and public health makes the control of this virus a high priority. To control BRSV, sanitary measures need to be combined with effective vaccination. However, current vaccines are unsatisfactory, especially in young calves with maternally derived antibodies (MDA). In this project, three novel BRSV vaccines, BRSV Immunostimulating Complexes (BRSV-ISCOMs), RSV nucleoprotein subunits (N nanorings) and live attenuated, genetically modified BRSV (rBRSV mutants) will be evaluated to identify the safest and most efficient vaccine protocol that will induce early, long-lasting clinical and virological protection against BRSV. All three vaccine approaches enable the development of a test for differentiation of infected from vaccinated animals (DIVA). This will facilitate vaccine evaluation in the field and sero-epidemiological investigations. It will also provide a key tool for any future disease control progammes.

牛呼吸道合胞病毒（BRSV）是小牛最重要的病毒性呼吸道病原体，导致欧洲养牛业的高发病率和死亡率。广泛使用抗生素来控制 BRSV 后的继发感染增加了出现抗生素耐药细菌的可能性。因此，BRSV 对经济、动物福利和公共卫生的影响使得控制该病毒成为当务之急。为了控制 BRSV，卫生措施需要与有效的疫苗接种相结合。然而，目前的疫苗并不令人满意，特别是对于具有母源抗体（MDA）的幼牛。在该项目中，将评估三种新型 BRSV 疫苗：BRSV 免疫刺激复合物 (BRSV-ISCOM)、RSV 核蛋白亚基（N 纳米环）和减毒活转基因 BRSV（rBRSV 突变体），以确定最安全、最有效的疫苗方案，从而产生针对 BRSV 的早期、持久的临床和病毒学保护。所有三种疫苗方法都可以开发区分受感染动物和接种疫苗动物的测试（DIVA）。这将有利于疫苗的现场评估和血清流行病学调查。它还将为任何未来的疾病控制计划提供关键工具。

项目成果

A bovine respiratory syncytial virus model with high clinical expression in calves with specific passive immunity.

• DOI: 10.1186/s12917-015-0389-6
• 发表时间: 2015-03-25
• 期刊: BMC veterinary research
• 影响因子: 2.6
• 作者: Blodörn K;Hägglund S;Gavier-Widen D;Eléouët JF;Riffault S;Pringle J;Taylor G;Valarcher JF
• 通讯作者: Valarcher JF

Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.

基于重组人RSV蛋白的疫苗安全性和功效评估，具有SH基因和亚基疫苗的缺失，基于重组人RSV蛋白：N纳米，P和M2-1在具有母体抗体的小腿中，n纳米，P和M2-1。

• DOI: 10.1371/journal.pone.0100392
• 发表时间: 2014
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Blodörn K;Hägglund S;Fix J;Dubuquoy C;Makabi-Panzu B;Thom M;Karlsson P;Roque JL;Karlstam E;Pringle J;Eléouët JF;Riffault S;Taylor G;Valarcher JF
• 通讯作者: Valarcher JF

Proteome analysis of bronchoalveolar lavage from calves infected with bovine respiratory syncytial virus-Insights in pathogenesis and perspectives for new treatments.

• DOI: 10.1371/journal.pone.0186594
• 发表时间: 2017
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Hägglund S;Blodörn K;Näslund K;Vargmar K;Lind SB;Mi J;Araínga M;Riffault S;Taylor G;Pringle J;Valarcher JF
• 通讯作者: Valarcher JF